Therapies targeting CTLA-4 have also been investigated in ovarian cancer; a combined treatment, which involves blockade of CTLA-4 and PD-1 and boosts the immune system, was found to induce tumor rejection in 75% of tumor models examined (97). The gene discussed is CTLA4; the disease is neoplasm.